HRP20230145T1 - Fuzijski polipeptid protiv raka - Google Patents
Fuzijski polipeptid protiv raka Download PDFInfo
- Publication number
- HRP20230145T1 HRP20230145T1 HRP20230145TT HRP20230145T HRP20230145T1 HR P20230145 T1 HRP20230145 T1 HR P20230145T1 HR P20230145T T HRP20230145T T HR P20230145TT HR P20230145 T HRP20230145 T HR P20230145T HR P20230145 T1 HRP20230145 T1 HR P20230145T1
- Authority
- HR
- Croatia
- Prior art keywords
- fusion protein
- seq
- amino acid
- group
- acid sequence
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 4
- 230000004927 fusion Effects 0.000 title claims 3
- 230000001093 anti-cancer Effects 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 claims 29
- 102000037865 fusion proteins Human genes 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 102000010956 Glypican Human genes 0.000 claims 9
- 108050001154 Glypican Proteins 0.000 claims 9
- 108050007237 Glypican-3 Proteins 0.000 claims 9
- 102000019298 Lipocalin Human genes 0.000 claims 9
- 108050006654 Lipocalin Proteins 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000007783 downstream signaling Effects 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 230000014616 translation Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (16)
1. Fuzijski protein naznačen time
što je fuzijski protein sposoban vezati i CD137 i glipikan-3 (GPC3), i
što fuzijski protein sadrži najmanje dvije podjedinice bilo kojim redoslijedom, pri čemu prva podjedinica sadrži lipokalinski mutein specifičan za CD137 koji ima najmanje 85% identičnosti sekvence sa sekvencom odabranom iz skupine koja se sastoji od SEQ ID NO: 18-33 i druga podjedinica sadrži imunoglobulin pune duljine, njegovu domenu koja veže antigen, ili lipokalinski mutein specifičan za GPC3.
2. Fuzijski protein prema zahtjevu 1, naznačen time što druga podjedinica sadrži lipokalinski mutein koji ima specifičnost vezanja za GPC3.
3. Fuzijski protein prema zahtjevu 2, naznačen time što fuzijski protein nadalje sadrži treću podjedinicu koja je
(i) fragment imunoglobulina-Fc,
(ii) specifično za CD137, ili
(iii) lipokalinski mutein koji ima specifičnost vezanja za CD137.
4. Fuzijski protein prema zahtjevu 2 ili 3, naznačen time što
lipokalinski mutein koji ima specifičnost vezanja za GPC3 sadrži aminokiselinsku sekvencu koja ima najmanje 85%
identičnost sekvence prema sekvenci odabranoj iz skupine koja se sastoji od SEQ ID NO: 4-17, ili ima najmanje 90%
identičnost sekvence prema sekvenci odabranoj iz skupine koja se sastoji od SEQ ID NO: 4-17, ili ima najmanje 95%
identičnost sekvence prema sekvenci odabranoj iz skupine koja se sastoji od SEQ ID NO: 4-17, ili je odabrana iz skupine koja se sastoji od SEQ ID NO: 4-17.
5. Fuzijski polipeptid prema bilo kojem od zahtjeva 1-4, naznačen time što
lipokalinski mutein koji ima specifičnost vezanja za CD137 sadrži sljedeći skup mutiranih aminokiselinskih ostataka u usporedbi s linearnom polipeptidnom sekvencom zrelog hNGAL (SEQ ID NO: 2):
Gln 28 → His; Leu 36 → Gln; Ala 40 → Ile; Ile 41 → Arg; Gln 49 → Ile; Tyr 52 → Met; Asn 65 → Asp; Ser 68 → Met; Leu 70 → Lys; Arg 72 → Asp; Lys 73 → Asp; Asp 77 → Met; Trp 79 → Asp; Arg 81 → Trp; Cys 87 → Ser; Asn 96 → Lys; Tyr 100 → Phe; Leu 103 → His; Tyr 106 → Ser; Lys 125 → Phe; Ser 127 → Phe; Tyr 132 → Glu; i Lys 134 → Tyr.
6. Fuzijski protein prema bilo kojem od zahtjeva 1-5, naznačen time što
(i) lipokalinski mutein koji ima specifičnost vezanja za CD137 ima najmanje 90% identičnosti sekvence sa aminokiselinskom sekvencom odabranom iz skupine koju čine SEQ ID NO: 18-33;
(ii) lipokalinski mutein koji ima specifičnost vezanja za CD137 ima najmanje 95% identičnosti sekvence sa aminokiselinskom sekvencom odabranom iz skupine koju čine SEQ ID NO: 18-33; ili
(iii) lipokalinski mutein koji ima specifičnost vezanja za CD137 sadrži aminokiselinsku sekvencu odabranu iz skupine koju čine SEQ ID NO: 18-33.
7. Fuzijski protein prema bilo kojem od zahtjeva 1-6, naznačen time što fuzijski polipeptid sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO: 48 ili aminokiselinsku sekvencu prikazanu u SEQ ID NO: 49.
8. Fuzijski protein prema bilo kojem od zahtjeva 1-7, naznačen time što je imunoglobulin monoklonsko antitijelo.
9. Fuzijski protein prema zahtjevu 8, naznačen time što
(a) monoklonsko antitijelo ima okosnicu IgG4,
pri čemu izborno okosnica IgG4 ima bilo koju od sljedećih mutacija odabranih iz skupine koju čine S228P, N297A, F234A, i L235A; ili
(b) monoklonsko antitijelo ima okosnicu IgG2,
pri čemu izborno okosnica IgG2 ima bilo koju od sljedećih mutacija odabranih iz skupine koju čine N297A, F234A, i L235A.
10. Fuzijski protein prema bilo kojem od zahtjeva 1-9, naznačen time što fuzijski protein sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO: 44, aminokiselinsku sekvencu prikazanu u SEQ ID NO: 45, aminokiselinsku sekvencu prikazanu u SEQ ID NO: : 46, ili aminokiselinsku sekvencu prikazanu u SEQ ID NO: 47.
11. Molekula nukleinske kiseline koja sadrži nukleotidnu sekvencu koja kodira fuzijski protein prema bilo kojem od zahtjeva 1-10.
12. Stanica domaćina koja sadrži molekulu nukleinske kiseline prema zahtjevu 11.
13. In vitro metoda proizvodnje fuzijskog proteina prema bilo kojem od zahtjeva 1-10, naznačena time što se fuzijski protein proizvodi počevši od nukleinske kiseline koja kodira fuzijski protein pomoću metoda genetskog inženjeringa, pri čemu se izborno fuzijski protein proizvodi u bakterijski ili eukariotski organizam domaćin i izoliran je iz tog organizma domaćina ili njegove kulture.
14. Fuzijski protein prema bilo kojem od zahtjeva 1-10, naznačen time što je za uporabu u liječenju raka.
15. Fuzijski protein za uporabu prema zahtjevu 14, naznačen time što sadrži
(i) istovremeno aktiviranje nizvodnih signalnih puteva CD137 i uključivanje GPC3-pozitivnih tumorskih stanica, što uključuje primjenu fuzijskog proteina ili pripravka koji sadrži takav fuzijski protein;
(ii) istovremenu kostimulaciju T stanica i uključivanje GPC3-pozitivnih tumorskih stanica, što uključuje primjenu fuzijskog proteina ili pripravka koji sadrži takav fuzijski protein;
(iii) istovremeno induciranje proliferacije T limfocita i uključivanje GPC3-pozitivnih tumorskih stanica, što uključuje primjenu fuzijskog proteina ili pripravka koji sadrži takav fuzijski protein; ili
(iv) usmjeravanje CD137 grupiranja i aktivacije T stanica na GPC3-pozitivne tumorske stanice, što uključuje primjenu fuzijskog proteina ili pripravka koji sadrži takav fuzijski protein.
16. Farmaceutski pripravak koji sadrži fuzijski protein prema bilo kojem od zahtjeva 1-10.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15167927 | 2015-05-18 | ||
| EP16150508 | 2016-01-08 | ||
| PCT/EP2016/061071 WO2016184882A1 (en) | 2015-05-18 | 2016-05-18 | Anti-cancer fusion polypeptide |
| EP16729794.4A EP3298030B1 (en) | 2015-05-18 | 2016-05-18 | Anti-cancer fusion polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230145T1 true HRP20230145T1 (hr) | 2023-04-28 |
Family
ID=56134305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230145TT HRP20230145T1 (hr) | 2015-05-18 | 2016-05-18 | Fuzijski polipeptid protiv raka |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10913778B2 (hr) |
| EP (2) | EP3298030B1 (hr) |
| JP (1) | JP6947642B2 (hr) |
| KR (1) | KR20180002855A (hr) |
| CN (1) | CN108112253B (hr) |
| AU (1) | AU2016262845B2 (hr) |
| BR (1) | BR112017020445A2 (hr) |
| CA (1) | CA2980838A1 (hr) |
| DK (1) | DK3298030T3 (hr) |
| ES (1) | ES2938525T3 (hr) |
| FI (1) | FI3298030T3 (hr) |
| HR (1) | HRP20230145T1 (hr) |
| HU (1) | HUE061108T2 (hr) |
| LT (1) | LT3298030T (hr) |
| MX (1) | MX2017014716A (hr) |
| PL (1) | PL3298030T3 (hr) |
| RS (1) | RS64002B1 (hr) |
| RU (2) | RU2021119777A (hr) |
| SG (1) | SG11201707426SA (hr) |
| SI (1) | SI3298030T1 (hr) |
| WO (1) | WO2016184882A1 (hr) |
| ZA (1) | ZA201706061B (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| WO2016177762A1 (en) * | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| US10501510B2 (en) | 2015-07-15 | 2019-12-10 | Pieris Pharmaceuticals Gmbh | Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof |
| AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
| CN110461873B (zh) * | 2017-01-03 | 2023-05-12 | 豪夫迈·罗氏有限公司 | 包含抗4-1bb克隆20h4.9的双特异性抗原结合分子 |
| EP3565840A1 (en) | 2017-01-06 | 2019-11-13 | Crescendo Biologics Limited | Single domain antibodies to programmed cell death (pd-1) |
| CA3050194A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Lipocalin muteins with binding affinity for lag-3 |
| WO2018134279A1 (en) * | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
| EP3710477A1 (en) * | 2017-11-13 | 2020-09-23 | Crescendo Biologics Limited | Single domain antibodies that bind to cd137 |
| GB201802573D0 (en) | 2018-02-16 | 2018-04-04 | Crescendo Biologics Ltd | Therapeutic molecules that bind to LAG3 |
| KR20200136949A (ko) | 2018-03-26 | 2020-12-08 | 4에스체 악티엔게젤샤프트 | 암 치료를 위한 hdac 억제제 및 cd137 작용제를 포함하는 배합물 |
| LT3830120T (lt) * | 2018-07-31 | 2023-07-10 | Pieris Pharmaceuticals Gmbh | Naujas sulietas baltymas specifinis cd137 ir pd-l1 atžvilgiu |
| BR112021016829A2 (pt) | 2019-02-26 | 2021-10-19 | Pieris Pharmaceuticals Gmbh | Proteínas de fusão, molécula de ácido nucleico, métodos de produção, de ativar simultaneamente as vias de sinalização, de coestimular células t, de induzir uma resposta de linfócitos e de induzir o aumento da citólise, composição farmacêutica e método para prevenir, melhorar ou tratar cânceres |
| WO2020208049A1 (en) * | 2019-04-12 | 2020-10-15 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecules comprising lipocalin muteins |
| PE20220500A1 (es) * | 2019-04-23 | 2022-04-07 | Lg Chemical Ltd | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 |
| CA3142513A1 (en) * | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| WO2023036043A1 (zh) * | 2021-09-09 | 2023-03-16 | 广东东阳光药业有限公司 | 抗癌结合分子及其应用 |
| WO2024064713A1 (en) * | 2022-09-21 | 2024-03-28 | Seagen Inc. | Novel fusion protein specific for cd137 and cd228 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2032831T5 (es) | 1986-08-19 | 2001-02-16 | Genentech Inc | Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas. |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| MX9605717A (es) | 1994-05-18 | 1998-05-31 | Inhale Therapeutic Syst | Metodos y composiciones para la formulacion de polvo seco de interferones. |
| DE4417598A1 (de) | 1994-05-19 | 1995-12-14 | Max Planck Gesellschaft | Verwendung des Tetracyclinpromotors zur stringent regulierten Produktion von rekombinanten Proteinen in prokaryontischen Zellen |
| WO1996023879A1 (en) | 1995-01-30 | 1996-08-08 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| WO1998016873A1 (fr) | 1996-10-14 | 1998-04-23 | Firm Forsat Ltd. | Procede de preparation de dispersions a base de composants chromogenes |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| CZ298681B6 (cs) | 1998-06-08 | 2007-12-19 | F. Hoffmann-La Roche Ag | Lécivo pro lécení infekcí chronické hepatitis C |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| WO2002024866A2 (en) | 2000-09-21 | 2002-03-28 | University Of Massachusetts | Method of inducing apoptosis in lymphoid cells |
| WO2002076489A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| AU2001298053A1 (en) | 2001-09-27 | 2003-04-14 | Pieris Proteolab Ag | Muteins of apolipoprotein D |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| US7288638B2 (en) * | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| JP2007284351A (ja) | 2004-07-27 | 2007-11-01 | Osaka Bioscience Institute | アミロイド蛋白質の凝集を抑制する物質とその作用 |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| WO2007038619A2 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| US20070087005A1 (en) | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| WO2007137170A2 (en) | 2006-05-20 | 2007-11-29 | Seattle Genetics, Inc. | Anti-glypican-3 antibody drug conjugates |
| ES2354653T3 (es) | 2006-08-01 | 2011-03-16 | Pieris Ag | Muteínas de lipocalina lacrimal y procedimientos para obtener las mismas. |
| WO2008015239A2 (en) * | 2006-08-01 | 2008-02-07 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| EP2178921B1 (en) | 2007-07-17 | 2016-01-06 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against glypican-3 |
| WO2009052390A1 (en) | 2007-10-19 | 2009-04-23 | Abbott Laboratories | Glycosylated mammalian ngal and use thereof |
| US8420051B2 (en) | 2008-06-24 | 2013-04-16 | Technische Universitaet Meunchen | Muteins of hNGAL and related proteins with affinity for a given target |
| CN102770764B (zh) | 2009-12-07 | 2016-04-20 | 皮里斯股份公司 | 对给定靶标具有亲和力的人脂质运载蛋白2（Lcn2，hNGAL）的突变蛋白 |
| KR101918024B1 (ko) | 2010-08-16 | 2018-11-14 | 피어이스 파마슈티컬즈 게엠베하 | 헵시딘 결합 단백질 |
| NZ729044A (en) * | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| EP2640740B1 (en) | 2010-11-15 | 2017-03-15 | Pieris Pharmaceuticals GmbH | Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) |
| WO2013174783A1 (en) * | 2012-05-23 | 2013-11-28 | Pieris Ag | Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3 |
| EP2928913A1 (en) * | 2012-12-10 | 2015-10-14 | Fred Hutchinson Cancer Research Center | Lipocalin fusion partners |
| WO2014116846A2 (en) * | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| TWI726842B (zh) * | 2014-04-07 | 2021-05-11 | 日商中外製藥股份有限公司 | 免疫活化抗原結合分子 |
| MX2017009767A (es) | 2015-01-28 | 2018-08-15 | Pieris Pharmaceuticals Gmbh | Nuevas proteínas específicas para la angiogénesis. |
| CR20170425A (es) | 2015-02-18 | 2017-11-22 | Sanofi Sa | Nuevas proteínas específicas para pioverdina y pioquelina |
| SG11201708334RA (en) | 2015-05-04 | 2017-11-29 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
| WO2016177762A1 (en) * | 2015-05-04 | 2016-11-10 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| KR20180008649A (ko) | 2015-05-18 | 2018-01-24 | 피어이스 파마슈티컬즈 게엠베하 | 글리피칸-3(gpc3)에 대해 친화도를 갖는 인간 리포칼린 2의 뮤테인 |
| TW201725212A (zh) | 2015-12-10 | 2017-07-16 | 第一三共股份有限公司 | 特異性於降鈣素基因相關胜肽的新穎蛋白 |
-
2016
- 2016-05-18 CN CN201680028941.3A patent/CN108112253B/zh active Active
- 2016-05-18 AU AU2016262845A patent/AU2016262845B2/en active Active
- 2016-05-18 DK DK16729794.4T patent/DK3298030T3/da active
- 2016-05-18 EP EP16729794.4A patent/EP3298030B1/en active Active
- 2016-05-18 KR KR1020177035641A patent/KR20180002855A/ko not_active Application Discontinuation
- 2016-05-18 LT LTEPPCT/EP2016/061071T patent/LT3298030T/lt unknown
- 2016-05-18 SG SG11201707426SA patent/SG11201707426SA/en unknown
- 2016-05-18 BR BR112017020445A patent/BR112017020445A2/pt active Search and Examination
- 2016-05-18 RS RS20230084A patent/RS64002B1/sr unknown
- 2016-05-18 RU RU2021119777A patent/RU2021119777A/ru unknown
- 2016-05-18 MX MX2017014716A patent/MX2017014716A/es unknown
- 2016-05-18 JP JP2017560331A patent/JP6947642B2/ja active Active
- 2016-05-18 ES ES16729794T patent/ES2938525T3/es active Active
- 2016-05-18 FI FIEP16729794.4T patent/FI3298030T3/fi active
- 2016-05-18 US US15/575,309 patent/US10913778B2/en active Active
- 2016-05-18 PL PL16729794.4T patent/PL3298030T3/pl unknown
- 2016-05-18 CA CA2980838A patent/CA2980838A1/en active Pending
- 2016-05-18 EP EP22216061.6A patent/EP4219535A1/en active Pending
- 2016-05-18 RU RU2017135539A patent/RU2754466C2/ru active
- 2016-05-18 HU HUE16729794A patent/HUE061108T2/hu unknown
- 2016-05-18 HR HRP20230145TT patent/HRP20230145T1/hr unknown
- 2016-05-18 SI SI201631659T patent/SI3298030T1/sl unknown
- 2016-05-18 WO PCT/EP2016/061071 patent/WO2016184882A1/en active Application Filing
-
2017
- 2017-09-06 ZA ZA2017/06061A patent/ZA201706061B/en unknown
-
2021
- 2021-02-05 US US17/169,209 patent/US11919931B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI3298030T1 (sl) | 2023-05-31 |
| CN108112253B (zh) | 2022-09-23 |
| ES2938525T3 (es) | 2023-04-12 |
| JP6947642B2 (ja) | 2021-10-13 |
| RU2754466C2 (ru) | 2021-09-02 |
| LT3298030T (lt) | 2023-02-27 |
| CN108112253A (zh) | 2018-06-01 |
| FI3298030T3 (fi) | 2023-02-22 |
| MX2017014716A (es) | 2018-06-28 |
| DK3298030T3 (en) | 2023-02-06 |
| HUE061108T2 (hu) | 2023-05-28 |
| WO2016184882A1 (en) | 2016-11-24 |
| ZA201706061B (en) | 2022-05-25 |
| AU2016262845B2 (en) | 2020-07-23 |
| AU2016262845A1 (en) | 2018-01-04 |
| JP2018519803A (ja) | 2018-07-26 |
| US20180148485A1 (en) | 2018-05-31 |
| RS64002B1 (sr) | 2023-03-31 |
| RU2017135539A3 (hr) | 2019-11-29 |
| RU2017135539A (ru) | 2019-06-18 |
| EP3298030A1 (en) | 2018-03-28 |
| SG11201707426SA (en) | 2017-10-30 |
| BR112017020445A2 (pt) | 2018-07-03 |
| KR20180002855A (ko) | 2018-01-08 |
| RU2021119777A (ru) | 2021-08-16 |
| US10913778B2 (en) | 2021-02-09 |
| US20210403516A1 (en) | 2021-12-30 |
| EP3298030B1 (en) | 2023-01-18 |
| EP4219535A1 (en) | 2023-08-02 |
| US11919931B2 (en) | 2024-03-05 |
| PL3298030T3 (pl) | 2023-05-08 |
| CA2980838A1 (en) | 2016-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230145T1 (hr) | Fuzijski polipeptid protiv raka | |
| KR102436129B1 (ko) | T 세포 수용체 및 이의 용도 | |
| HRP20210011T1 (hr) | Metoda i pripravci za staničnu imunoterapiju | |
| HRP20201392T1 (hr) | Fgf21 fuzijski proteini dugotrajnog djelovanja i farmaceutski pripravci koji sadrže iste | |
| Kazane et al. | Self-assembled antibody multimers through peptide nucleic acid conjugation | |
| JP2018519803A5 (hr) | ||
| Siegemund et al. | An optimized antibody-single-chain TRAIL fusion protein for cancer therapy | |
| HRP20200640T1 (hr) | De-imunizirane, okosnice podjedinice shiga toksina a i molekule koje ciljaju stanice koje ih sadrže | |
| HRP20230590T1 (hr) | Novi fuzijski protein specifičan za cd137 i pd-l1 | |
| US9644020B2 (en) | Human Tim-3 fusion protein capable of blocking Tim-3 signaling pathway | |
| HRP20151227T1 (hr) | Sastavi i postupci uporabe za terapeutska protutijela | |
| JP2014523238A (ja) | インターフェロンと標的化修飾ユビキチンタンパク質とを含むヒト融合タンパク質 | |
| MX2023007282A (es) | Moleculas de union al antigeno especificas para la variante ror1. | |
| CN103237808A (zh) | 抗癌融合蛋白 | |
| JP2022528030A (ja) | 多機能性融合タンパク質及びその使用 | |
| KR20200120648A (ko) | 항pd-1/항her2 천연항체 구조 헤테로다이머계의 이중특이성 항체 및 그 제조방법 | |
| US20240166754A1 (en) | Il12rb1-binding molecules and methods of use | |
| CN115103852A (zh) | Prame tcr受体和其用途 | |
| AU2023251563A1 (en) | Biased IL2 muteins methods and compositions | |
| CA3025124A1 (en) | Herpesvirus with modified glycoprotein h for propagation in a cell | |
| NZ724196A (en) | Uti fusion proteins | |
| CN108264560B (zh) | 一种结合cd3和cd28的双功能分子及其应用 | |
| JP2017508446A (ja) | 二機能性融合タンパク質及びその製造方法並びに使用 | |
| CA3234552A1 (en) | Heterodimeric fc cytokines and uses thereof | |
| HRP20191671T1 (hr) | Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) |